Cargando…

Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy

PURPOSE: To investigate the effect of systemic therapy on health-related quality of life (HRQoL) in patients with advanced esophagogastric cancer in daily clinical practice. This study assessed the HRQoL of patients with esophagogastric cancer during first-line systemic therapy, at disease progressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pape, Marieke, Vissers, Pauline A. J., Slingerland, Marije, Haj Mohammad, Nadia, van Rossum, Peter S. N., Verhoeven, Rob H. A., van Laarhoven, Hanneke W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425291/ https://www.ncbi.nlm.nih.gov/pubmed/37578590 http://dx.doi.org/10.1007/s00520-023-07963-5

Ejemplares similares

SOURCE beyond first‐line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first‐line palliative systemic therapy
por: Kuijper, Steven C., et al.
Publicado: (2022)

A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma
por: Pape, Marieke, et al.
Publicado: (2022)

A population-based comparison of patients with metastatic esophagogastric carcinoma between Japan and the Netherlands
por: Pape, Marieke, et al.
Publicado: (2023)

Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)
por: Stroes, Charlotte I, et al.
Publicado: (2022)

Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study
por: Kroese, Tiuri E., et al.
Publicado: (2022)

Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
por: ter Veer, Emil, et al.
Publicado: (2016)

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population‐based study
por: Pape, Marieke, et al.
Publicado: (2022)

Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study
por: Pape, Marieke, et al.
Publicado: (2023)

Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis
por: Haj Mohammad, N., et al.
Publicado: (2015)

Population-based study of treatment and outcome of recurrent oesophageal or junctional cancer
por: Pape, Marieke, et al.
Publicado: (2022)

The impact of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer
por: Doeve, Benthe H., et al.
Publicado: (2023)

A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577
por: Pape, Marieke, et al.
Publicado: (2022)

Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review
por: ter Veer, Emil, et al.
Publicado: (2018)

The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2016)

Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
por: Dijksterhuis, Willemieke P. M., et al.
Publicado: (2020)

Clinical variation in the organization of clinical pathways in esophagogastric cancer, a mixed method multiple case study
por: Luijten, J. C. H. B. M., et al.
Publicado: (2022)

Treatment decision‐making during outpatient clinic visit of patients with esophagogastric cancer. The perspectives of clinicians and patients, a mixed method, multiple case study
por: Luijten, Josianne C. H. B. M., et al.
Publicado: (2022)

Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients
por: Klaassen, Remy, et al.
Publicado: (2018)

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
por: Schokker, Sandor, et al.
Publicado: (2019)

ASO Author Reflections: Role of Local Treatment for Oligometastatic Esophagogastric Cancer
por: Kroese, Tiuri E., et al.
Publicado: (2022)

Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study
por: Keywani, Kammy, et al.
Publicado: (2023)

On the Receiving End of Autonomy and Law
por: van Laarhoven, Hanneke W. M., et al.
Publicado: (2017)

Informing Patients With Esophagogastric Cancer About Treatment Outcomes by Using a Web-Based Tool and Training: Development and Evaluation Study
por: van de Water, Loïs F, et al.
Publicado: (2021)

Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer
por: Kroese, Tiuri E., et al.
Publicado: (2022)

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2017)

Priority of lymph node dissection for advanced esophagogastric junction adenocarcinoma with the tumor center located below the esophagogastric junction
por: Cai, Ming-Zhi, et al.
Publicado: (2019)

Rapid stromal remodeling by short‐term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma
por: Steins, Anne, et al.
Publicado: (2020)

Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study
por: Dijksterhuis, Willemieke P M, et al.
Publicado: (2021)

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer
por: van Zweeden, A. A., et al.
Publicado: (2018)

Incidence, Stage, Treatment, and Survival of Noncardia Gastric Cancer
por: van Velzen, Merel J. M., et al.
Publicado: (2023)

Can proximal Gastrectomy Be Justified for Advanced Adenocarcinoma of the Esophagogastric Junction?
por: Sato, Yuya, et al.
Publicado: (2018)

Real-world treatment attrition rates in advanced esophagogastric cancer
por: Tsang, Erica S, et al.
Publicado: (2020)

Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction
por: Zheng, Yi-Han, et al.
Publicado: (2022)

Trends in treatment and overall survival among patients with proximal esophageal cancer
por: de Vos-Geelen, Judith, et al.
Publicado: (2019)

First report of in-tissue esophagogastric transit migration of an over-the-scope clip
por: Zimmer, Vincent
Publicado: (2021)

Who should provide care for patients receiving palliative chemotherapy? A qualitative study among Dutch general practitioners and oncologists
por: Wind, Jan, et al.
Publicado: (2018)

Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
por: Hackshaw, A, et al.
Publicado: (2005)

Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit
por: Kalff, Marianne C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bvuk2uthtnud3gipfvbtig6b0u